Nephros PE Ratio 2010-2025 | NEPH
Current and historical p/e ratio for Nephros (NEPH) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nephros PE ratio as of August 08, 2025 is 32.50.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Nephros PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-08-08 | 3.90 | 55.71 | |
| 2025-03-31 | 1.72 | $0.07 | 24.57 |
| 2024-12-31 | 1.47 | $0.00 | 0.00 |
| 2024-09-30 | 1.71 | $-0.09 | 0.00 |
| 2024-06-30 | 2.11 | $-0.13 | 0.00 |
| 2024-03-31 | 2.19 | $-0.14 | 0.00 |
| 2023-12-31 | 3.46 | $-0.15 | 0.00 |
| 2023-09-30 | 1.48 | $-0.09 | 0.00 |
| 2023-06-30 | 1.55 | $-0.38 | 0.00 |
| 2023-03-31 | 1.07 | $-0.46 | 0.00 |
| 2022-12-31 | 1.16 | $-0.63 | 0.00 |
| 2022-09-30 | 0.91 | $-0.74 | 0.00 |
| 2022-06-30 | 1.53 | $-0.55 | 0.00 |
| 2022-03-31 | 4.40 | $-0.55 | 0.00 |
| 2021-12-31 | 5.90 | $-0.41 | 0.00 |
| 2021-09-30 | 8.77 | $-0.38 | 0.00 |
| 2021-06-30 | 10.15 | $-0.38 | 0.00 |
| 2021-03-31 | 6.65 | $-0.45 | 0.00 |
| 2020-12-31 | 8.58 | $-0.52 | 0.00 |
| 2020-09-30 | 7.23 | $-0.46 | 0.00 |
| 2020-06-30 | 8.39 | $-0.44 | 0.00 |
| 2020-03-31 | 6.30 | $-0.39 | 0.00 |
| 2019-12-31 | 9.95 | $-0.44 | 0.00 |
| 2019-09-30 | 8.05 | $-0.51 | 0.00 |
| 2019-06-30 | 5.49 | $-0.50 | 0.00 |
| 2019-03-31 | 4.32 | $-0.45 | 0.00 |
| 2018-12-31 | 5.13 | $-0.54 | 0.00 |
| 2018-09-30 | 5.43 | $-0.27 | 0.00 |
| 2018-06-30 | 5.47 | $-0.27 | 0.00 |
| 2018-03-31 | 3.78 | $-0.27 | 0.00 |
| 2017-12-31 | 4.05 | $-0.09 | 0.00 |
| 2017-09-30 | 2.70 | $-0.36 | 0.00 |
| 2017-06-30 | 2.07 | $-0.36 | 0.00 |
| 2017-03-31 | 3.46 | $-0.45 | 0.00 |
| 2016-12-31 | 3.29 | $-0.54 | 0.00 |
| 2016-09-30 | 3.33 | $-0.63 | 0.00 |
| 2016-06-30 | 2.31 | $-0.72 | 0.00 |
| 2016-03-31 | 2.34 | $-1.08 | 0.00 |
| 2015-12-31 | 1.94 | $-1.08 | 0.00 |
| 2015-09-30 | 3.33 | $-2.88 | 0.00 |
| 2015-06-30 | 6.39 | $-2.97 | 0.00 |
| 2015-03-31 | 5.40 | $-2.70 | 0.00 |
| 2014-12-31 | 7.11 | $-2.88 | 0.00 |
| 2014-09-30 | 6.98 | $-1.53 | 0.00 |
| 2014-06-30 | 10.62 | $-1.53 | 0.00 |
| 2014-03-31 | 5.76 | $-1.71 | 0.00 |
| 2013-12-31 | 3.82 | $-2.25 | 0.00 |
| 2013-09-30 | 10.80 | $-2.43 | 0.00 |
| 2013-06-30 | 8.10 | $-2.79 | 0.00 |
| 2013-03-31 | 7.11 | $-2.97 | 0.00 |
| 2012-12-31 | 10.71 | $-2.52 | 0.00 |
| 2012-09-30 | 12.60 | $-2.25 | 0.00 |
| 2012-06-30 | 18.00 | $-1.98 | 0.00 |
| 2012-03-31 | 9.45 | $-1.89 | 0.00 |
| 2011-12-31 | 6.21 | $-3.06 | 0.00 |
| 2011-09-30 | 17.10 | $-10.62 | 0.00 |
| 2011-06-30 | 6.75 | $-12.06 | 0.00 |
| 2011-03-31 | 3.96 | $-13.32 | 0.00 |
| 2010-12-31 | 18.00 | $-13.50 | 0.00 |
| 2010-09-30 | 50.40 | $-7.20 | 0.00 |
| 2010-06-30 | 64.80 | $-7.20 | 0.00 |
| 2010-03-31 | 198.00 | $-7.20 | 0.00 |
| 2009-12-31 | 140.40 | $-5.40 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.041B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $233.709B | 27.40 |
| Boston Scientific (BSX) | United States | $152.828B | 36.44 |
| Stryker (SYK) | United States | $144.352B | 29.38 |
| EssilorLuxottica (ESLOY) | France | $136.813B | 0.00 |
| Medtronic (MDT) | Ireland | $119.054B | 16.89 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.435B | 0.00 |
| Haleon (HLN) | United Kingdom | $42.853B | 24.46 |
| ResMed (RMD) | United States | $41.628B | 29.73 |
| GE HealthCare Technologies (GEHC) | United States | $32.872B | 15.45 |
| Agilent Technologies (A) | United States | $32.560B | 21.23 |
| Terumo (TRUMY) | Japan | $27.538B | 32.63 |
| Koninklijke Philips (PHG) | Netherlands | $25.845B | 17.10 |
| Insulet (PODD) | United States | $21.612B | 72.43 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.663B | 12.52 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.829B | 0.00 |
| Baxter (BAX) | United States | $12.168B | 9.40 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.599B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.150B | 26.26 |
| Lantheus Holdings (LNTH) | United States | $3.889B | 10.52 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.364B | 23.53 |
| Prestige Consumer Healthcare (PBH) | United States | $3.227B | 14.32 |
| Perrigo (PRGO) | Ireland | $3.102B | 7.75 |
| ICU Medical (ICUI) | United States | $2.786B | 18.97 |
| Haemonetics (HAE) | United States | $2.601B | 11.61 |
| LeMaitre Vascular (LMAT) | United States | $2.089B | 44.80 |
| AtriCure (ATRC) | United States | $1.755B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.624B | 10.22 |
| Green Thumb Industries (GTBIF) | United States | $1.509B | 64.82 |
| Curaleaf Holdings (CURLF) | Canada | $1.368B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.240B | 17.67 |
| Phibro Animal Health (PAHC) | United States | $1.139B | 14.56 |
| Acuren (TIC) | United States | $1.138B | 0.00 |
| Neogen (NEOG) | United States | $1.103B | 17.52 |
| BioLife Solutions (BLFS) | United States | $1.086B | 2268.00 |
| InMode (INMD) | Israel | $0.892B | 8.25 |
| Valneva SE (VALN) | France | $0.775B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.746B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.714B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.560B | 0.00 |
| Owens & Minor (OMI) | United States | $0.548B | 4.54 |
| ZimVie (ZIMV) | United States | $0.530B | 20.45 |
| Surmodics (SRDX) | United States | $0.506B | 0.00 |
| CeriBell (CBLL) | United States | $0.473B | 0.00 |
| SNDL (SNDL) | Canada | $0.441B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.414B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.393B | 13.54 |
| Evolus (EOLS) | United States | $0.382B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.367B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.347B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.341B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.275B | 20.88 |
| Canopy Growth (CGC) | Canada | $0.256B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.253B | 0.00 |
| Omeros (OMER) | United States | $0.251B | 0.00 |
| Cerus (CERS) | United States | $0.232B | 0.00 |
| Brainsway (BWAY) | Israel | $0.222B | 58.80 |
| Quanterix (QTRX) | United States | $0.221B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.220B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.214B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.203B | 0.00 |
| Exagen (XGN) | United States | $0.202B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 15.06 |
| High Tide (HITI) | Canada | $0.176B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.170B | 0.00 |
| Biote (BTMD) | United States | $0.158B | 4.72 |
| TriSalus Life Sciences (TLSI) | United States | $0.149B | 0.00 |
| Safety Shot (SHOT) | United States | $0.138B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.136B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.133B | 0.00 |
| Jin Medical (ZJYL) | China | $0.103B | 0.00 |
| MacroGenics (MGNX) | United States | $0.097B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 12.33 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| Agape ATP (ATPC) | $0.068B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Veru (VERU) | United States | $0.055B | 0.00 |
| Zynex (ZYXI) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 14.11 |
| Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.017B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |